You would like to read
- Optimus Pharma launched a new Anti-Parkinson's Drug in India
- Drugs manufacturer from Hyderabad on overdrive
- Prashant Reddy (Bunty) zeroed in on social responsibilities and development
- GiveIndia supports 56L Indians in response to the COVID crisis
- Development starts at grassroots level: BJP Gachibowli division contestant V Gangadhar Reddy
Hyderabad (Telangana) [India], May 25 (ANI/PRNewswire): Optimus Pharma on the 19th of May 2021 received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild to Moderate Covid-19 patients.
With severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus Pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave nod for conducting the trial on mild to moderate patients.
As per the clinical trial protocol approved, 2500 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be maximum for 29 days from randomisation, the release said.
"Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients," Chairman & Managing Director - Dr D Srinivas Reddy said.
In the previous press release, company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.
Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand - FAVICOVID). The company aims to do the same with Molnupiravir to cater to the rising demand of Anti-Viral drugs against SARS-CoV-2 in the Indian market.
With the cooperation of the government and the stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, the management hopes to deliver the product in India by leveraging the solid distribution strength across the country.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
